Agilent's $240 Million Proscia Deal Buys a Digital Pathology Platform

Agilent Technologies is paying for a software layer that could connect more of the pathology workflow, not simply another laboratory product. The company agreed to acquire Proscia for $240 million in cash at closing, with up to $30 million of additional payments tied to performance milestones.

Proscia provides enterprise digital pathology software that links slide scanners, laboratory information systems and image-analysis tools. Agilent said the platform serves clinical and life-sciences customers across the United States and Europe. The source report put Proscia's trailing revenue above $18 million and its growth rate above 20%, based on Evercore ISI estimates.

Small acquisition, strategic fit

The upfront price is about 13 times the reported trailing revenue before considering the contingent payment. That simple calculation is not a full valuation because Proscia's earnings, cash flow and revenue definition were not disclosed. It does show that Agilent is paying for growth and strategic access rather than near-term scale.

The attraction is distribution. Proscia serves more than 4,000 laboratories, hospitals and clinics, along with 16 of the top 20 pharmaceutical companies, according to the source article. Agilent already sells Dako pathology instruments and reagents, so management expects cross-selling and a more integrated workflow.

Competition sets the context

Roche previously agreed to buy PathAI for as much as $1.05 billion, signaling that major diagnostics companies see software and AI analysis as increasingly important to pathology. The prices are not directly comparable because the targets and deal structures differ, but they show that digital pathology has become a strategic category.

Agilent describes Proscia as a high-growth, high-margin software business. Investors should treat that as a management claim until the acquired operation's contribution appears in reported segment results. Integration must preserve Proscia's software relationships while making the combined instrument, reagent and data offering more useful to customers.

The transaction is expected to close early in Agilent's 2027 fiscal year, subject to customary conditions. The near-term financial effect should be modest for a company of Agilent's size. The longer-term test is whether cross-selling lifts recurring software revenue and strengthens customer retention without diluting returns on the purchase price.